Compare SLVM & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLVM | CAPR |
|---|---|---|
| Founded | 1898 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2021 | 2011 |
| Metric | SLVM | CAPR |
|---|---|---|
| Price | $38.44 | $6.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $54.00 | $44.63 |
| AVG Volume (30 Days) | 269.1K | ★ 5.7M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,351,000,000.00 | N/A |
| Revenue This Year | $0.93 | N/A |
| Revenue Next Year | $1.54 | $3.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.53 | $2.96 |
| 52 Week High | $56.80 | $40.37 |
| Indicator | SLVM | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 32.07 |
| Support Level | $36.78 | $4.23 |
| Resistance Level | $40.13 | $30.39 |
| Average True Range (ATR) | 1.52 | 0.81 |
| MACD | 0.05 | 0.38 |
| Stochastic Oscillator | 31.47 | 71.48 |
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.